Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-02-28
2006-02-28
Weddington, Kevin E. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07005443
ABSTRACT:
3-(2-aminoethyl)-1H-indazol-5-ols useful for treating elevated intraocular pressure and glaucoma are disclosed.
REFERENCES:
patent: 4690931 (1987-09-01), Wick et al.
patent: 5151444 (1992-09-01), Ueno et al.
patent: 5276051 (1994-01-01), Lesieur et al.
patent: 5296504 (1994-03-01), Stjernschantz et al.
patent: 5352708 (1994-10-01), Woodward et al.
patent: 5422368 (1995-06-01), Stjernschantz et al.
patent: 5494928 (1996-02-01), Bos
patent: 5571833 (1996-11-01), Kruse et al.
patent: 5874477 (1999-02-01), McConnell et al.
patent: 5889052 (1999-03-01), Klimko et al.
patent: 5902815 (1999-05-01), Olney et al.
patent: 6391872 (2002-05-01), Marfat
patent: 6664286 (2003-12-01), May et al.
patent: 6696476 (2004-02-01), Chen et al.
patent: WO 94/13275 (1994-06-01), None
patent: WO 98/30548 (1998-07-01), None
patent: WO 98/31354 (1998-07-01), None
patent: WO 98/31354 (1998-07-01), None
patent: WO 99/59499 (1999-11-01), None
patent: WO 99/59499 (1999-11-01), None
patent: 00/12482 (2000-03-01), None
patent: 00/16761 (2000-03-01), None
patent: WO 00/12482 (2000-03-01), None
patent: WO 00/12482 (2000-03-01), None
patent: WO 00/16761 (2000-03-01), None
patent: WO 00/16761 (2000-03-01), None
Ainsworth, C., “Substituted β-Aminoethylindazoles”, J. Amer. Chem. Soc., 80:965-967 (1958).
Ainsworth, C., “The Indazole Analog Of Serotonin”, Journal Of The American Chemical Society, vol. 79, pp 5245-5247 (1957) [XP-000881644] [D2].
Bennetau, B., et al., “Une Voie De Synthese Simple Et Rapide De Phenols Meta Acyles”, Tetrahedron, 50:1179-1188 (1994).
Bodar, Nicholas, et al., “Improved Delivery Through Biological Membranes, XVII3. A Site-Specific Chemical Delivery System as a Short-Acting Mydriatic Agent”, Pharm. Res., 168-173 (1984).
Bowen et al., “Nonlinear regression using spreadsheets”, Trends In Pharmacological Sciences, 16:413 (1995).
Buchheit, K-H, et al., “The Serotonin 5-HT4 Receptor. 2. Structure—Activity Studies of the Indole Carbazimidiamide Class of Agonists1”, J. Med. Chem., 38:2331-2338 (1995).
Chemical Abstract, 1988:94460, “Synthesis and radioprotective activity of .beta.-(3-indazolyl)ethylamine derivatives” [XP002162456,] [D3].
Fiorella, et al., “Role of 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs II: reassessment of LSD false positives”, Psychopharmacology, 121:357 (1995).
Griffin, B. W., et al., “Pharmacological Characterization of an FP Prostaglandin Receptor on Rat Vascular Smooth Muscle Cells (17r5) Coupled to Phosphoinositide Turnover and Intracellular Calcium Mobilization”, J. Pharmacol. Exp. Ther., 286:411-418 (1998).
Gupta, Y.K., et al., “Therapeutic Potentials of 5-HT Receptor Modulators”, Indian Journal Of Pharmacology, vol. 26, No. 2, pp 94-107 (Jun. 1, 1994) [D6].
Hamano, H. and Okuda, S., “Studies on Dimethoxyphenylaminoalcohols. II. 1) Syntheses and Relative Configurations of 1-Dimethoxyphenyl-3-(alkylamino)butanols”, Chem. Parm. Bull., 22:1348-1359 (1974).
Johnson, M. P., et al., “Binding To The Serotonin 5-HT2 Receptor By The Enantioners of 125I-DOI”, Neuropharmacology, 26:1803-1806 (1987).
Sakito, et al., “Asymmetric Reduction Of Oxime Ethers. Distinction Of Anti And Syn Isomers Leading To Enantiomeric Amines”, Tetrahedron Letters, 29:223-224 (1988).
Villalobos, A., et al., “Novel Benzisoxazole Derivatives as Potent and Slective Inhibitors of Acetylcholinesterase”, J. Med. Chem., 37:2721-2734 (1994).
Wilkerson et al., “Anti-inflammatory phospholipase-A2 inhibitors. II. Design, synthesis and structure-activity relationship”, Eur. J. Med. Chem., 27:595-610 (1992).
Wrona, M. Z. and Dryhurst, Glenn, “Further Insights into the Oxidation Chemistry of 5-Hydroxytryptamine”, Journal of Pharmaceutical Sciences, 77:911-917 (1988).
Wrona, M. Z. and Dryhurst, G., “Oxidation Chemistry of 5-Hydroxytryptamine. 1. Mechanism and Products Formed at Micromoloar Concentrations” J. Org. Chem, 52:2817-2825 (1987).
Banerji, A., et al., “Synthesis Of 2-Hydroxy-4, 6-Dimethoxycrotonophenone A New Class Of Natural Products From Dysophylla Stellata Benth.”, Synthetic Communications, 10(11):851-856 (1980).
Bruce, D., B., et al., “Reactions in Fused Aluminium Chloride-Sodium Chloride”, Journal of The Chemical Society, 2403-2406 (1953).
Buchanan, G. L., “The Dakin-West Reaction”, Chem. Soc. Rev., 17:91-109 (1988).
“Improved Ocular Drug Delivery with Prodrugs”, Drugs And The Pharmaceutical Sciences, edited by Kenneth B. Sloan, vol. 53:221-254 (1992).
Peshkovsky, A. and McDermott, A. E., NMR Spectroscopy in the Presence of Strong Ac Electric Fields: Degree of Alignment of Polar Molecules, J. Phys. Chem., 103:8604-8611 (1999).
Wrona, M.Z. and Dryhurst, G., “Oxidation of Serotonin by Superoxide Radical: Implications to Neurodegenerative Brain Disorders”, Chem. Res. Toxicol., 11(6):639-650 (1998).
Feng Zixia
May Jesse A.
Alcon Inc.
Ryan Patrick M.
Weddington Kevin E.
LandOfFree
5-Hydroxy indazole derivatives for treating glaucoma does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 5-Hydroxy indazole derivatives for treating glaucoma, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 5-Hydroxy indazole derivatives for treating glaucoma will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3685334